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or, more likely, an inherited series of traits
with a number ofgenes involved." The other
half, then, may be an environmental compo-
nent of autoimmune disease. Researchers
believe that agents from outside the body,
whether microbes, chemicals, or radiation,
may also be found to play a major role in the
development ofautoimmune disease.
Where to Start?
Uncertainty in this new field reaches even to
the fundamental questions of what an
autoimmune disease is and how many peo-
ple are affected. Researchers debate the num-
ber of autoimmune diseases and how many
people they affect due partly to different def-
initions and purposes for the estimates.
When a group of epidemiologists at Johns
Hopkins, including Rose, prepared to review
the epidemiology of autoimmune disease in
the United States, they came up with 28 dis-
eases with "direct or indirect evidence of
autoimmune pathogenesis" (of these, 4 had
no epidemiologic data to review). By con-
trast, the American Autoimmune Related
Diseases Association, an advocacy group,
suggests that autoimmunity is the underlying
cause of more than 80 chronic diseases that
afflict some 50 million Americans. Some
researchers believe there may be evidence to
support the higher estimates and suggest that
as more is learned about autoimmune disor-
ders, individual diseases may turn out to be
part of large categories of rare diseases with
similar manifestations.
One of the reasons for these widely dif-
fering numbers is a paucity ofbasic epidemi-
ologic data that is largely due to the fact that
most individual autoimmune diseases are
quite rare. By the admittedly conservative
estimates of the Johns Hopkins researchers,
published in the September 1997 issue of
Clinical Immunologv and Immunopathologv,
only three autoimmune diseases-rheuma-
toid arthritis, Graves disease (hyperthy-
roidism), and Hashimoto thyroiditis
(hypothyroidism)-afflict as many as 1 or 2
Americans in 100. Another handful of
autoimmune diseases, such as multiple scle-
rosis, type 1 diabetes mellitus, and vitiligo,
are estimated to afflict between 1 and 5
Americans in 1,000, but most ofthe remain-
ing diseases afflict less than a few Americans
per 100,000. The true numbers are probably
higher.
Some ofthe relatively minor symptoms of
autoimmune diseases such as fatigue, joint
and back pain, and muscular ache are simply
withstood by sufferers without visits to the
doctor's office or hospital. Even when patients
enter the medical system, the often complex
manifestations ofautoimmune diseases resem-
ble more common nonimmune disorders and
arelikely to lead to misdiagnoses.
Identifying specific environmental risk
factors for autoimmune diseases is highly
speculative. What data exist from epidemio-
logic studies are often contradictory or show
weak effects ofindividual risk factors. In fact,
most candidates for environmental links to
autoimmune disease come primarily from a
few well-known large-scale chemical or drug
exposures that produced autoimmune syn-
dromes. For example, in 1981, 35,000 peo-
ple in Spain developed acute "toxic oil syn-
drome" after ingesting contaminated rape-
seed oil. Their initial symptoms, including
fever, fatigue, and joint and muscle pain,
were similar to symptoms seen in autoim-
mune diseases. In most cases, patients were
eventually categorized as having a "lupus-
like" or "scleroderma-like" disorder.
(Systemic scleroderma is an autoimmune dis-
ease that manifests itself through a thicken-
ing of the skin.) A similar syndrome was
caused in the United States in 1989 by cont-
aminants in the dietary supplement L-tryp-
tophan. A large number of medicinal drugs,
approximately 40 of which are still in use
today, have also produced lupus-like syn-
dromes in some patients. Most prominent
among the more than 70 drugs that have
caused lupus-like syndromes are pro-
cainamide, a cardiac antiarrhythmic medi-
cine, and hydralazine, an antihypertensive
drug.
Occupational exposure to vinyl chlo-
ride also has been linked to a lupus-like
syndrome, and silica dust is known to
induce scleroderma. But because these syn-
dromes differ in some respects from the
spontaneous diseases and because they gen-
erally resolve when the chemical or drug
exposure is ended, researchers wonder
whether these syndromes provide real
insight into the etiology ofthe spontaneous
or idiopathic diseases.
The Prototypical Autoimmune
Disease
SLE is considered the prototypical systemic
autoimmune disease. It is a highly variable
disease, with symptoms that change over
time as the immune system attacks different
internal organs, the skin, joints, and muscles.
SLE patients may manifest only a few lupus
symptoms, rather than the four or more that
may generally be required for inclusion in a
study. This is one reason that epidemiologic
researchers, who have to select subjects using
well-defined and standardized criteria, fail to
include many patients whom rheumatolo-
gists are treating for SLE.
Symptoms of SLE range from mild to
life-threatening. The disease can involve
joints, muscles, and the skin and, in more
serious cases, major organs (such as the heart,
lungs, and kidneys) and the nervous system.
Major symptoms such as kidney or nervous
system inflammation can be treated and
resolved with corticosteroids or immunosup-
pressive drugs. However, these drugs have
significant side effects and so are not used for
other symptoms, forcing patients to live with
joint pain, overwhelming fatigue, and gener-
al achiness throughout the body that can be
only partly relieved by nonsteroidal anti-
inflammatory drugs (NSAIDs) such as
aspirin and ibuprofen. "It's very much like
coming down with the flu," says Virginia
Ladd, executive director of the American
Autoimmune Related Diseases Association
and a lupus patient herself. "That's how a
person with lupus feels a lot ofthe time: not
sick enough to go to bed, but with that flu-
like feeling."
The joint, skin, and muscle symptoms
can be traced to chronic inflammation,
which may be mediated by antibodies gener-
ated against the body's own cells. In fact, the
presence oflarge numbers ofsuch antibodies,
particularly antinuclear antibody and anti-
double-stranded DNA, is one of the
strongest diagnostic criteria for SLE. The
most common organ involvement is a kidney
disorder called glomerulonephritis, wherein
antibodies direct white blood cells to destroy
kidney tissue and to form complexes with
other molecules that clog up the filtration
system of the kidney. If the kidneys are
involved to a significant degree in SLE,
patients may have to undergo dialysis and
may even die from the disease.
SLE, despite its relatively low prevalence,
has been pushed to the forefront ofautoim-
mune research with respect to environmental
links because lupus-like syndromes are
among the most common autoimmune dis-
orders related to side effects of medicinal
drugs or to accidental or occupational expo-
sures to toxicants. Although none of these
agents has yet been shown to be a risk factor
in idiopathic SLE, they do provide candi-
dates for study.
Cooper and colleagues at the University
of North Carolina at Chapel Hill, Duke
University Medical Center in Durham, the
East Carolina University School ofMedicine
in Greenville, and the Medical University of
South Carolina in Charleston are conducting
an epidemiologic study ofrecently diagnosed
SLE patients in North Carolina and South
Carolina. They have cast a wide net, looking
for both hormonal and environmental risk
factors. Based on animal studies on the
effects ofestrogen on disease progression and
evidence that estrogen replacement therapy
may be associated with an increased risk of
SLE in postmenopausal women, the
researchers are looking at a number offactors
involving both hormone medication and a
woman's own hormonal profile, including
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age at menarche, menstrual cycle patterns,
and age at menopause. Other candidate risk
factors such as exposure to silica, UV light,
and some solvents and metals were chosen
based on evidence from occupational and
experimental studies. Data collection from
the 250 SLE patients and 350 controls,
involving interviews and blood sampling,
was recently completed and the researchers
are now analyzing the data of what will be
the largest population-based epidemiologic
study ofSLE to date.
A More Selective Disease
In contrast to SLE, type 1 diabetes (also
known as insulin-dependent diabetes melli-
tus [IDDM]) is an organ-specific disease;
only cells in the pancreas appear to be
attacked by the immune system. What's
known about how type 1 diabetes acts is that
antibodies to the insulin-producing beta cells
of the pancreas direct white blood cells to
infiltrate the region and destroy the beta
cells. When the beta cells have been
destroyed, patients must then control glucose
metabolism by regular injections of insulin.
This is an imperfect solution, and unexpect-
ed fluctuations in glucose concentrations can
put great stress on other organs.
Patients are thus forced to live within
rigid schedules; missing a scheduled snack or
meal or undergoing unexpected exertion or
excitement can quickly trigger drastic hypo-
glycemia (low blood sugar), which can result
in coma and possibly permanent brain injury.
Even when patients follow their regimens
strictly, they are at the mercy oftheir injected
insulin and other medications, which are
hard pressed to supply the body's tissues with
the precise glucose levels they require. This
means that many patients are subject to long-
term complications of diabetes such as
increased risk ofheart attack and stroke, dete-
rioratingvision, kidney failure, and infection.
Type 1 diabetes is the second most com-
mon chronic childhood disease and, unlike
most autoimmune disorders, afflicts a slight-
ly higher number of males than females. It
affects approximately 150,000 children in
the United States and typically is diagnosed
between the ages of 10 and 13. But Roland
Tisch, an immunologist at the University of
North Carolina at Chapel Hill, says, "When
a person is diagnosed with overt diabetes, the
disease process has most likely been going on
for a number ofyears."
A number ofenvironmental factors, pri-
marily viruses and dietary factors, have been
linked to type 1 diabetes. Among the virus
candidates are those that cause mumps,
mononucleosis, and rubella (German
measles). There is even a good candidate
mechanism, called molecular mimicry, for
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how a virus might induce autoimmune type
1 diabetes. The theory is based on the obser-
vation that some viruses have elements in
common with beta cells. For example, a pro-
tein found on the rubella virus is structurally
similar to one found in pancreatic cells; it is
thought that this mimicry might confuse the
immune system into attacking beta cells. But
no virus has been definitively shown to cause
type 1 diabetes in humans.
The only nonmicrobial agents that have
been implicated in autoimmune type 1 dia-
betes are foods, and the evidence has not
been particularly strong. Cow's milk, N-
nitroso compounds, gluten, fat, and proteins
have all raised red flags in small epidemio-
logic studies, but subsequent study has not
conclusively shown any ofthese agents to be
a clear risk factor for type 1 diabetes.
Echoing researchers of other autoimmune
diseases, Tisch says, "No one is going to dis-
pute that there is an environmental link, but
there isn't any definitive proof out there
linking IDDM and viruses or any other
environmental agents."
NotJustYour Grandmother's Disease
Rheumatoid arthritis, thought by many to be
a disease of elderly women, actually affects
people of all ages, including a considerable
number of men (about 25% of cases).
Rheumatoid arthritis is considered a systemic
disease because it can affect joints through-
out the body and has other systemic effects
including fatigue, weight loss, and anemia.
But it can also be thought ofas organ-specif-
ic because it selectively destroys a membrane
called the synovium that lines the joints. An
antibody called rheumatoid factor appears to
initiate destruction of the synovium. The
ensuing inflammation involves the abnormal
growth and division of synovial cells as well
as the arrival of white blood cells, which
release enzymes that are thought to destroy
the cartilage and cause the joint to fuse.
The first symptoms of this process-
joint inflammation (arthritis) and pain in the
extremities typically appear in patients
between 25 and 50 years ofage. The disease
is usually symmetrical, affecting both hands
or both feet equally. Patients find that their
joints are stiff for hours each morning. The
typical treatment for mild arthritis is rest and
NSAIDs. Corticosteroids and immunosup-
pressive drugs are reserved for severe discom-
fort or disability and must be reduced and
discontinued as soon as possible. These mea-
sures provide relief for 75% of patients, but
the drugs do not slow the progression ofthe
disease, and 10% of patients will ultimately
become disabled as their joints are destroyed.
As with other immune diseases, the only
risk factors for rheumatoid arthritis that have
been extensively studied are genetic. There is
strong evidence that variations in certain
genes, especially in combination, predispose
the bearers to develop rheumatoid arthritis.
Researchers are now turning to the question
ofwhich environmental factors might inter-
act with a susceptible genetic profile. Among
the candidates are infectious agents, immu-
nizations, estrogen replacement therapy,
smoking, and alcohol consumption. Various
studies have failed to turn up strong or even
consistent effects for any ofthese risk factors.
However, researchers believe that combina-
tions ofdifferent low-risk environmental fac-
tors interacting with a susceptible genetic
profile are needed to trigger the disease. "It
may be that you have to have the right genes
that put you at high risk, and it could then
be 25 different things in the environment
that give that susceptible person the disease,"
says rheumatologist Beth Karlson ofBrigham
and Women's Hospital in Boston,
Massachusetts.
The Difference between the Sexes
Rheumatoid arthritis predominantly strikes
women, usually later in life. This is the com-
mon factor that links most autoimmune dis-
eases. The ratio ofwomen to men afflicted is
3:1 for rheumatoid arthritis, 9:1 for lupus,
and 25:1 for autoimmune thyroiditis.
Researchers point out that women's immune
systems appear to be more aggressive.
"Females live longer and their immune sys-
tems are better," says David Lawrence, an
immunologist at the Wadsworth Center, a
part of the New York State Department of
Health in Albany. "But being able to make
antibodies better and to make a stronger cell-
mediated immune response [means] they
also have an increased possibility of getting
autoimmune disease."
Suspicion for the difference in incidence
between the sexes understandably falls on
hormones, especially estrogen. However,
attempts to elucidate the role of estrogen in
human autoimmune disease have typically
turned up weak effects or conflicting results.
For example, offive epidemiologic studies of
perimenopausal hormone replacement thera-
py and the risk of rheumatoid arthritis, one
showed an increased risk, one showed a pro-
tective effect, and three found no effect. On
the other hand, studies of SLE, scleroderma,
and Raynaud phenomenon (periodic spasms
of the smallest arteries in the hands and feet
that lead to sensations of cold or pain) have
consistently shown slight increases in risk
after hormone replacement therapy.
Researchers are also continuing to look for
links between women's hormonal profiles and
autoimmune disease because animal studies
have demonstrated that estrogen can theoreti-
cally alter regulation of the major immune
system cells, the T and B lymphocytes [see
EHP 107(Suppl 5):681-686 (1999)].
Determining the exact role of estrogen will
depend on finding the mechanisms by which
the hormone helps turn the immune system
against the body.
WhereThings Go Awry
The immune system consists of a vast array
of defense mechanisms: large white blood
cells such as macrophages, neutrophils, and
leukocytes, which can ingest antigens such as
invading microbes; smaller white blood cells
that include T lymphocytes (or T cells),
which scan for and attack specific antigens,
and B lymphocytes (or B cells), which gener-
ate individualized antibodies to ensure con-
tinued and rapid responses to antigens; and a
host of small molecules called cytokines,
which complement and assist the leukocytes
in these processes.
In order for this aggressive system to
work, the immune system must learn to dis-
tinguish "self' antigens (specific molecules
on the body's own cells) from "nonself' anti-
gens (microbes or molecules from outside
the body) in a process called tolerance. For T
cells, which have primary surveillance
responsibility, this education takes place in
the thymus. In order to leave the thymus, T
cells must recognize and therefore not react
to the major histocompatibility complex
(MHC) unique to each person that is
found on the surface of thymus cells. By a
process that science has still not completely
described, T cells that react strongly to self-
MHC molecules are functionally suppressed
or eliminated in the thymus. The current
assumption is that they are stimulated to
undergo apoptosis, or programmed cell
death. A parallel process in the bone marrow
is believed to remove autoreactive B cells.
But the occasional autoreactive lympho-
cyte makes it out into the blood or lymphatic
circulation, even in healthy people. The
body then appears to call on a complex set of
interactions between the lymphocyte and
other molecules and cells to neutralize the
lymphocyte. Two main mechanisms have
been uncovered: anergy, whereby the T cell
is made less responsive to antigens, and sup-
pression, whereby other lymphocytes and
natural killer cells use cytokines to inhibit the
capacity of autoreactive lymphocytes to
respond to self-antigens.
While much mystery remains regarding
how the immune system operates, there has
been enough progress that it is possible to
suggest where environmental factors might
disrupt the immune system's tolerance for its
own antigens. Bruce Richardson, a rheuma-
tologist and immunologist at the University
of Michigan and the Ann Arbor Veterans
Affairs Medical Center, describes three broad
opportunities for environmental substances
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to interfere with this tolerance. The first is to
prevent the establishment oftolerance in the
thymus, the second is to alter gene expres-
sion in the cells that participate in the
immune response, and the third is to alter
the MHC proteins that signal "self' on the
surface of the body's cells, either by directly
modifying the proteins or by altering the
genes that encode them [see EHP 107(Suppl
5):737-742 (1999)].
Although no one study is considered a
front-runner at this point, there are some
animal data to support each ofthese mech-
anisms. For example, the MRL-/pr mouse
has a defective form ofFas, a protein neces-
sary for apoptotic cell death in the thymus.
Without Fas, autoreactive T cells are not
weeded out by apoptosis, and these mice
develop a lupus-like disease and die at an
early age. Humans with defects in the gene
that encodes Fas develop autoimmune dis-
orders in which red blood cells and other
blood components are destroyed. However,
there is, as ofyet, no evidence to link these
disorders with Fas-mediated apoptosis ofT
cells in the thymus, much less to suggest
that an environmental agent contributed to
the process.
An idea that particularly intrigues
researchers of the first mechanism has been
advanced by Robert Rubin, an immunologist
at The Scripps Research Institute in LaJolla,
California. Rubin studies drugs that have
been shown to cause lupus-like syndromes in
patients. Research into the mechanism of
these syndromes has been stymied by the fact
that the various drugs have no obvious simi-
larities ofstructure or pharmacologic activity.
Rubin hypothesized that metabolites ofthese
drugs could interfere with the mechanisms
that teach T-cell tolerance in the thymus.
(This idea arose from recent revelations that
T cells are generated in the thymus through-
out life; it had been believed that T-cell pro-
duction ceased soon after birth.) In an article
in the 15 April 1997 issue of the Journal of
Clinical Investigation, Rubin demonstrated
that injecting procainamide hydroxylamine
(a metabolite of procainamide) directly into
the thymus ofmice will produce a syndrome
like that found in human drug-induced
lupus [see EHP 107(Suppl 5):803-806
(1999)]. Whether this mechanism is at work
in the human drug-induced disease or
whether it could be a mechanism that other
environmental agents use to contribute to
idiopathic lupus is conjecture. "We're quite
optimistic but we don't have much evidence
for it," says Rubin. "It's preliminary and
quite controversial."
Richardson has demonstrated that envi-
ronmental agents could alter gene expres-
sion in T cells outside the thymus-the
second possible mechanism for interference
with tolerance-to help cause autoimmuni-
ty. Based on suggestions that the methyla-
tion ofDNA which is essential for proper
expression of proteins-is altered in
autoimmune disease, Richardson and his
colleagues exposed T cells to a DNA
methylation-inhibiting drug in vitro. The
resulting autoreactive cells were transplant-
ed to healthy mice with identical MHC
profiles, where they induced a disease that
resembled lupus. This research was report-
ed in the June 1996 issue of the Journal of
ClinicalInvestigation.
The question ofwhether this would hap-
pen in humans obviously couldn't be tested,
so in experiments published in the August
1997 issue ofArthritis and Rheumatism, the
researchers asked a related question: do the
drugs that cause lupus in people have these
same effects, namely, inhibiting DNA methy-
lation and making mouse T cells autoreac-
tive? Says Richardson, "We looked at pro-
cainamide and hydralazine, both of which
cause lupus in a significant number ofpeople,
and the answer was yes." Although such ani-
mal results are a long way from proving that
the drugs induce lupus in humans by inhibit-
ing DNA methylation or that this mecha-
nism is at work in idiopathic lupus, they have
provided Richardson's group with the moti-
vation to search for the genes and gene prod-
ucts that may be affected by these drugs.
As for the third autoimmune mechanism,
whereby the MHC proteins that signal "self'
on the surface of the body's cells are altered,
thereby making them targets for lympho-
cytes, there are a number of examples that
implicate a process called haptenization.
Certain small, foreign molecules called hap-
tens, although not antigens by themselves, are
able to interact with MHC proteins and
change their structure. T and B cells identify
cells with altered MHC proteins as nonself
antigens and mount immune attacks on
them. The mechanism by which a hapten
binds to a larger protein to produce a recog-
nizable antigen has been demonstrated for a
number of molecules, including vinyl chlo-
ride, metabolites of phenytoin, and ions of
mercury, gold, and nickel. There is no evi-
dence yet that haptenization contributes to
autoimmune disease in vivo, but haptens have
been shown to alter self-proteins and to
induce auto-antibodies in some experimental
in vitro systems.
Autoi'muneAnimal Models
To illuminate whether any of these mecha-
nisms are actually used by environmental
agents to contribute to autoimmune dis-
eases, immunologists and other scientists
hope to use models of animals that have
genetic predispositions to develop such dis-
eases. It is generally agreed that lupus
research may benefit the most from such
models as there are several mouse strains
that develop lupus-like syndromes. The best
known model is the New Zealand
black/New Zealand white mouse-50% of
the female mice of this species die of
glomerulonephritis by 34 weeks ofage. The
MRL-/pr mouse, with its mutation in the
gene for Fas, also develops a very severe
autoimmune syndrome early in life, though
females and males are equally affected.
Lawrence suggests that newer animal vari-
ations may be the best models for studying
the subtle effects of environmental agents.
For example, many strains of New Zealand
mixed mice have been created by selective
Color is the key. Two chromosomal loci for susceptibility to SLE have been linked to coat color in New
Zealand black/New Zealand white mice. Different strains of these mice have varying susceptibilities to
developing lupus and are being bred to study the possible effects of environmental exposures on the
development of SLE in humans.
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breeding of the New Zealand black/New
Zealand white mice and their descendants.
Among these, there are some strains in which
only a small percentage of the mice develop
autoimmune disease and in which the disease
progresses slowly, more like the human dis-
ease profile. Similarly, the MRL-Ipr mouse
without the Fas gene mutation develops a less
severe disease later in life.
The Long RoadAhead
At the close ofthe September 1998 NIEHS
workshop on environmental links to
autoimmune diseases, the participants came
up with research needs in five main cate-
gories that included development of innov-
ative and appropriate research tools, estab-
lishment ofan autoimmune disease registry
or surveillance system, development of
strategies for screening chemicals for
autoimmune activity, development of an
emergency response strategy to gain infor-
mation on accidental exposures that may
lead to autoimmune responses, and autoim-
mune hypothesis-driven research in occupa-
tionally exposed groups and in experimental
animals [see EHP 107(Suppl 5):811-814
(1999)]. The participants clearly felt that
the first four needs would have to be met
before the last could begin to be addressed.
Researchers appear to be setting out into
this new field of study-autoimmunity and
environmental health-with only a few bits
ofintriguing information and a multitude of
basic questions. They know some of the
genes involved and they have hints about a
few of the mechanisms and chemicals that
might be involved. But as immunologist
Frederick Miller ofthe U.S. Food and Drug
Administration points out, "You may have
multiple environmental exposures interacting
with multiple genetic risk factors to result in
the complete expression of an autoimmune
disease." This suggests that answers will be
slow in coming, but Miller is hopeful: "The
beauty of immune diseases is that they are
theoretically preventable because they are all
gene-environment interactions." The key, he
says, will be to find the genes and environ-
ments that combine to cause diseases, after
which it will be possible to tell susceptible
people which drugs, chemicals, dietary sup-
plements, or foods they need to avoid.
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